Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling
- PMID: 34087551
- DOI: 10.1016/j.jpba.2021.114171
Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling
Abstract
Introduction: A range of opioids are commonly prescribed to manage chronic pain, but individual patient responses vary greatly, especially in older populations. One source of that variability are differences in absorption, metabolism and excretion, i.e. pharmacokinetics. Blood, plasma and serum concentrations of opioids allow that variability to be quantified and may be used to optimise opioid dosing. As an aid to that process, there is an unmet need to rapidly quantify several opioids and their metabolites in a single analytical method.
Aims: To develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of tramadol, oxycodone, fentanyl and their major metabolites in various human matrices.
Methods: Sample preparation involved adding three deuterated internal standards followed by protein precipitation with 100 % acetonitrile, evaporation and reconstitution. Separation of analytes via LC was achieved on a reversed phase column via binary gradient elution using 0.005 % formic acid in water and 100 % acetonitrile as mobile phases. Analytes were detected via MS/MS with multiple reaction monitoring (MRM).
Results: The method was accurate with the inter-day and intra-day accuracy of quality control samples (QCs) below 15 %. It was also precise with inter-day and intra-day coefficient of variation below 15 %. The lower limit of quantification (LLOQ) was 0.2 ng/mL for all analytes except tramadol and its metabolites, where the LLOQ was 10 ng/mL. Recovery was greater than 88 % for all analytes, except for O-desmethyltramadol (81 %). Analytes were stable over four freeze-thaw cycles, for 24 h on the bench top and for 24 h post-preparation. The inter- and intra-day variability of concentrations determined in blood and plasma were within 84-124%, whereas the inter- and intra-day variability for blood samples prepared using volumetric absorptive micro-sampling (VAMS) compared to those prepared from whole blood ranged between 83-122%.
Conclusion: A LC-MS/MS method is described that is able to accurately and precisely quantify a number of commonly prescribed opioids and their major metabolites in plasma and whole blood, including whole blood collected using VAMS.
Keywords: LC–MS/MS; Metabolite; Opioid; Plasma; VAMS; Whole blood.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors have no potential conflicts of interest that may be relevant to the contents of this manuscript.
Similar articles
-
Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases.Clin Chem Lab Med. 2017 Aug 28;55(9):1324-1331. doi: 10.1515/cclm-2016-0990. Clin Chem Lab Med. 2017. PMID: 28080998
-
Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:174-180. doi: 10.1016/j.jchromb.2015.11.035. Epub 2015 Nov 23. J Chromatogr B Analyt Technol Biomed Life Sci. 2016. PMID: 26655109
-
Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry.Ther Drug Monit. 2008 Jun;30(3):333-40. doi: 10.1097/FTD.0b013e31816e2d4b. Ther Drug Monit. 2008. PMID: 18520605
-
HPLC-UV assay of tramadol and O-desmethyltramadol in human plasma containing other drugs potentially co-administered to participants in a paediatric population pharmacokinetic study.J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Nov 1;1184:122971. doi: 10.1016/j.jchromb.2021.122971. Epub 2021 Oct 7. J Chromatogr B Analyt Technol Biomed Life Sci. 2021. PMID: 34649173 Review.
-
Validation and reproducibility of an LC-MS/MS method for emixustat and its three deaminated metabolites in human plasma.Bioanalysis. 2018 Nov 1;10(22):1803-1817. doi: 10.4155/bio-2018-0159. Epub 2018 Oct 16. Bioanalysis. 2018. PMID: 30325202 Review.
Cited by
-
Volumetric Absorptive Microsampling in Toxicology.Toxics. 2024 Dec 30;13(1):25. doi: 10.3390/toxics13010025. Toxics. 2024. PMID: 39853024 Free PMC article. Review.
-
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.Cancers (Basel). 2021 Dec 14;13(24):6281. doi: 10.3390/cancers13246281. Cancers (Basel). 2021. PMID: 34944899 Free PMC article.
-
Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2.PeerJ. 2024 May 30;12:e17446. doi: 10.7717/peerj.17446. eCollection 2024. PeerJ. 2024. PMID: 38827306 Free PMC article.
-
MWCNTs-CTAB and HFs-Lac Nanocomposite-Modified Glassy Carbon Electrode for Rutin Determination.Biosensors (Basel). 2022 Aug 11;12(8):632. doi: 10.3390/bios12080632. Biosensors (Basel). 2022. PMID: 36005028 Free PMC article.
-
Population Pharmacokinetic Model for Tramadol and O-desmethyltramadol in Older Patients.Eur J Drug Metab Pharmacokinet. 2022 May;47(3):387-402. doi: 10.1007/s13318-022-00756-x. Epub 2022 Feb 15. Eur J Drug Metab Pharmacokinet. 2022. PMID: 35167052 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials